Amazon Pares Back On Ambitious India Edtech Dreams

Amazon.Com, Inc (NASDAQ:AMZN) will shut down Amazon Academy, an online learning platform it launched in India for high-school students…
  • Amazon.Com, Inc (NASDAQ:AMZN) will shut down Amazon Academy, an online learning platform it launched in India for high-school students last year, TechCrunch reports.
  • Amazon will wind down the edtech service in the country in a phased manner starting August 2023. 
  • Those who signed up for the current academic batch will receive a full refund.
  • Also Read: Amazon Launches Logistics Network In India After Walmart-Backed Flipkart
  • Amazon officially launched Academy, previously called JEE Ready, in 2021 after testing the platform since mid-2019. Academy sought to help students prepare for entry into the nation’s prestigious engineering colleges.
  • Byju’s, Unacademy, and Vedantu dominate India’s education market.
  • Meta Platforms Inc (NASDAQ:META) Facebook also invested in Unacademy, a Bangalore-based startup that offers online learning classes. 
  • Alphabet Inc (NASDAQ: GOOG) (NASDAQ: GOOGL) Google, which invested in Indian edtech startup Cuemath, also partnered with CBSE to train more than 1 million teachers in India and offer a range of free tools like G-Suite for Education, Google Classroom and YouTube to help digitize the education experience in the nation.
  • Amazon looks to cut about 10,000 jobs and began eliminating roles in some divisions, including devices and services. 
  • Amazon also shut down teams that make AWS tutorials and other online courses.
  • Price Action: AMZN shares closed higher by 1.00% at $94.13 on Wednesday.
  • Photo by christian wiediger via unsplash
Total
0
Shares
Related Posts
Read More

NIO, Evolution Petroleum And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session

U.S. stock futures traded lower this morning on Wednesday. Here are some big stocks recording losses in today’s pre-market trading session. Evolution Petroleum Corporation (NYSE: EPM) dipped 13.9% to $7.62 in pre-market trading after reporting downbeat fourth-quarter results.

ACB

Read More

Satsuma Pharmaceuticals Says Analysis Of Results From Recently-Completed Summit Phase 3 Efficacy Trial Of Sts101 For The Acute Treatment Of Migraine Shows Differentiating Robust, Sustained Antimigraine Effects On Clinically Important Secondary Endpoint…

Satsuma Pharmaceuticals Provides STS101 Development Program and Corporate Update Further analysis of results from recently-completed SUMMIT Phase 3 efficacy trial of STS101 for the acute treatment of migraine shows

STSA